These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1554831)

  • 1. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury.
    Boucher BA; Kuhl DA; Hickerson WL
    Clin Infect Dis; 1992 Feb; 14(2):458-63. PubMed ID: 1554831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin pharmacokinetics in patients with severe burn injuries.
    Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
    Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.
    Walstad RA; Aanderud L; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(5):543-9. PubMed ID: 3069478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin elimination in patients with burn injury.
    Brater DC; Bawdon RE; Anderson SA; Purdue GF; Hunt JL
    Clin Pharmacol Ther; 1986 Jun; 39(6):631-4. PubMed ID: 3709027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aztreonam pharmacokinetics in burn patients.
    Friedrich LV; White RL; Kays MB; Brundage DM; Yarbrough D
    Antimicrob Agents Chemother; 1991 Jan; 35(1):57-61. PubMed ID: 2014982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of variables for potential impact on vancomycin pharmacokinetics in thermal or inhalation injury.
    Elder K; Hill DM; Hickerson WL
    Burns; 2018 May; 44(3):658-664. PubMed ID: 29097070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amikacin population pharmacokinetics among paediatric burn patients.
    Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
    Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.
    Gomez DS; Sanches-Giraud C; Silva CV; Oliveira AM; da Silva JM; Gemperli R; Santos SR
    J Antibiot (Tokyo); 2015 Mar; 68(3):143-7. PubMed ID: 25227503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers.
    Adamis G; Papaioannou MG; Giamarellos-Bourboulis EJ; Gargalianos P; Kosmidis J; Giamarellou H
    Int J Antimicrob Agents; 2004 Feb; 23(2):144-9. PubMed ID: 15013039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
    Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
    Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic variability of extended interval tobramycin in burn patients.
    Bracco D; Landry C; Dubois MJ; Eggimann P
    Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ceftazidime in burn patients.
    Dailly E; Pannier M; Jolliet P; Bourin M
    Br J Clin Pharmacol; 2003 Dec; 56(6):629-34. PubMed ID: 14616422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of antibiotics in critically ill patients.
    van Dalen R; Vree TB
    Intensive Care Med; 1990; 16 Suppl 3():S235-8. PubMed ID: 2289997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of teicoplanin in burn patients.
    Potel G; Moutet J; Bernareggi A; Le Normand Y; Meigner M; Baron D
    Scand J Infect Dis Suppl; 1990; 72():29-34. PubMed ID: 2151064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.